Corvus Pharmaceuticals CRVS Accrued expenses and other liabilities
Accrued expenses and other liabilities at other companies
Other financials
Where this comes from
Reported directly by Corvus Pharmaceuticals in its filing.
Tagged under the XBRL concept us-gaap:IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities.
The official record: Corvus Pharmaceuticals’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →
Ask your AI about Corvus Pharmaceuticals's accrued expenses and other liabilities.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Corvus Pharmaceuticals's accrued expenses and other liabilities?
- Corvus Pharmaceuticals (CRVS) reported accrued expenses and other liabilities of $499K in Q1 2026.
- How has Corvus Pharmaceuticals's accrued expenses and other liabilities changed year-over-year?
- Corvus Pharmaceuticals's accrued expenses and other liabilities increased by 241.8% year-over-year, from $146K to $499K.
- What is the long-term trend for Corvus Pharmaceuticals's accrued expenses and other liabilities?
- Over 3 years (2021 to 2025), Corvus Pharmaceuticals's accrued expenses and other liabilities has grown at a 74.1% compound annual growth rate (CAGR), from -$523K to $2.76M.